Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy

Simply Wall St.04-09

Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626182261?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-09 17:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626182261","market":"sg","top_or_hot":-1,"title":"Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy","media":"Simply Wall St.","content":"<div>\n<p>Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 17:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","article_id":"2626182261","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626182261","pubTimestamp":1775727454,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication.\nSee our latest analysis for Mesoblast.\nDespite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","MESO":"Mesoblast Limited","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK7067":"生物科技","BK7508":"医药生物股","BK7501":"新冠治疗股","MSB.AU":"MESOBLAST LTD","LABU":"三倍做多标普生物-Direxion"},"translate_title":"FDA批准杜氏肌营养不良症新Ryoncil试验后评估Mesoblast的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1,"LABU":1.5,"MESO":1.5},"content_text":"Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication. See our latest analysis for Mesoblast. Despite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest sentiment is cooling in the short term while investors reassess longer term potential and risk around the pipeline. If this kind of biotech catalyst has your attention, it could be a good moment to see what else is moving in healthcare by checking out 10 healthcare AI stocks With Mesoblast shares easing after a strong 3 year run and still trading at a steep discount to analyst targets and intrinsic estimates, investors need to ask whether this weakness is a buying opportunity or whether the market is already assuming future growth. AdvertisementMost Popular Narrative: 47% Undervalued With Mesoblast trading at A$2.03 versus a narrative fair value of A$3.83, the current price sits well below what this widely followed view assumes.  The heart failure program for rexlemestrocel L, with RMAT designation and FDA feedback that existing trial data could support an accelerated approval filing alongside a planned confirmatory study, gives Mesoblast a potential entry into a very large cardiovascular market. Outcomes would primarily influence long term revenue scale and the path to sustainable earnings.  Read the complete narrative. Curious what earnings profile and margin lift would need to materialise to back that valuation gap? The narrative leans on rapid revenue expansion, sharp profitability swings and a future earnings multiple that assumes investor confidence holds up. The full story ties those moving parts into one cohesive fair value path. Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Ryoncil building beyond early uptake and on future trial outcomes, where slower adoption or setbacks could quickly challenge the view that it is 47% undervalued. Find out about the key risks to this Mesoblast narrative. Another Angle On Valuation The narrative points to a fair value of A$3.83, yet on simple sales metrics Mesoblast looks expensive, with a P/S of 28.3x versus 16.6x for the Australian biotech industry and 22.8x for peers, and a fair ratio of 5.7x. That gap leaves investors weighing potential upside against clear valuation risk, so which side of that trade-off feels more realistic to you? See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at Apr 2026Next Steps With sentiment pulled in different directions by trial milestones and valuation gaps, it pays to move quickly, review the data yourself and decide where you stand, starting with the 3 key rewards Looking for more investment ideas? If Mesoblast has sparked your interest, do not stop here. The broader market is full of opportunities that could better match your goals and risk comfort.  Target reliable income by scanning for companies with stronger yield profiles and balance sheets using the 7 dividend fortresses. Hunt for potential mispriced opportunities by searching across a focused set of companies in the screener containing 14 high quality undiscovered gems. Prioritise resilience by zeroing in on companies with steadier risk profiles through the 9 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626182261","isCrawlerRequest":true}